Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that a low-dose intermittent finasteride regimen significantly reduced hirsutism scores in adolescent girls with PCOS or idiopathic hirsutism, with similar efficacy but potentially safer and less expensive than continuous administration.

This review discusses the latest understanding of androgenetic alopecia, including stem cell niches in hair follicles, and highlights emerging treatments like growth factors and platelet-rich plasma without new clinical findings.

This study found that tamsulosin, finasteride use, and aging are significantly associated with increased risk of intraoperative floppy iris syndrome during cataract surgery, while doxazosin does not appear to pose this risk.

This study found that coadministration of 5α-reductase inhibitors with oral testosterone in oil significantly increases serum testosterone levels in medically castrated men compared to testosterone alone, with food intake minimally affecting these levels.

This article discusses androgenetic alopecia and reports no new clinical results.

This study found that three months of oral finasteride treatment significantly decreased dihydrotestosterone levels and hair growth in hirsute women without negatively affecting gonadotropin secretion.

This study identified previously unknown phase I and phase II metabolites of finasteride in human bile and urine using a specialized bile collection technique and advanced mass spectrometry analysis.

This study found that compounds 21–23 and 25 exhibited strong 5α-reductase II inhibition in vitro and significantly reduced rat prostate weight, performing comparably to finasteride.

This study developed a pharmacokinetic/pharmacodynamic model for finasteride, concluding that finasteride's nonlinear pharmacokinetics are likely due to its saturable binding to 5alphaR2.

This study found that combining 5-alpha reductase inhibitors with alpha-blockers provided the best symptomatic relief and reduced the risk of clinical progression for BPH, while PDE5 inhibitors could offset sexual side effects.

This study found that invasomes enhanced the iontophoretic transdermal delivery of finasteride in rabbits, increasing AUC and T1/2 compared to oral suspension.

This study developed and validated a reliable method to measure finasteride levels in human plasma, which was successfully used to assess its pharmacokinetics after a 5 mg dose in healthy volunteers.

Finasteride effectively lowers specific hormone levels, helping monitor treatment progress.

Reduced androgens linked to kinky hair disorder and hair loss; 5a-reductase inhibitors may help.

This study suggests that inhibitors of steroidogenic enzymes may have therapeutic potential for certain behavioral disorders linked to dopaminergic hyperfunction, despite concerns about their endocrine impacts.

Finasteride doesn't affect antipyrine metabolism, so interactions with cytochrome P-450 enzyme drugs are unlikely.

This study concluded that Flaxin tablets and the reference formulation are bioequivalent in terms of absorption rate and extent when administered as a single 5 mg dose to healthy male volunteers.

In this study, a new Finasteride conjugate showed stronger inhibition of 5α-reductase and similar reduction of prostate hyperplasia in rats compared to Finasteride, with potentially improved toxicity.

This study found that certain steroidal compounds, especially 10a–10c, demonstrated strong antiandrogenic activity by binding to the androgen receptor and reducing prostate weight in a hamster model.

This study found that two different 5 mg finasteride tablet formulations are bioequivalent in terms of the rate and extent of absorption in healthy volunteers.

This study found that novel compounds moderately inhibited 5α-reductase type 1 activity compared to finasteride, offering valuable data on structure-activity relationships.

This study found that chronic administration of finasteride affected the isotopic composition of testosterone and nandrolone metabolites, impacting the drug-testing outcomes in athletic contexts.

This study identified new oxidative derivatives of finasteride, including a newly discovered metabolite, by using the fungus Macrophomina phaseolina.

This study reports the crystal structure and geometric parameters of a modified Finasteride derivative, highlighting significant differences in dihedral angles compared to its solvated analog and computational models.

Finasteride can cause low platelet count in rare cases.

This study designed a novel model for 5a-reductase enzyme inhibitors using pharmacophore and 3D QSAR techniques, potentially allowing for improved prediction and development of drug therapies targeting benign prostatic hyperplasia.

This review discusses U.S. patents in organic process development published in July and August 2004 and reports no new experimental results.

This study concluded that two different pharmaceutical formulations of finasteride were bioequivalent in terms of rate and extent of absorption based on pharmacokinetic evaluations in a randomized crossover study with 38 volunteers.

This study found that biotransformation of finasteride by Aspergillus niger produced two metabolites with different levels of lipoxygenase inhibition, suggesting potential for developing more potent derivatives.

This review summarizes expert opinions on the use of approved pharmacologic treatments alongside hair transplantation, highlighting their potential to enhance hair density and regrowth speed while reducing further hair loss, but reports no new clinical trial results.